Can-Fite Biopharma Ltd (CANF) Expected to Post Earnings of -$0.13 Per Share

Wall Street brokerages forecast that Can-Fite Biopharma Ltd (NASDAQ:CANF) will announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma posted earnings of ($0.10) per share during the same quarter last year, which would indicate a negative year over year growth rate of 30%. The business is expected to report its next earnings results on Friday, June 7th.

According to Zacks, analysts expect that Can-Fite Biopharma will report full-year earnings of ($0.55) per share for the current financial year. For the next financial year, analysts anticipate that the firm will report earnings of $0.12 per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Can-Fite Biopharma.

Separately, HC Wainwright reissued a “buy” rating on shares of Can-Fite Biopharma in a report on Tuesday, March 26th.



NASDAQ:CANF traded down $0.01 during midday trading on Wednesday, hitting $0.55. 1,100 shares of the stock were exchanged, compared to its average volume of 307,727. Can-Fite Biopharma has a one year low of $0.54 and a one year high of $1.73.

About Can-Fite Biopharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Further Reading: Net Asset Value

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.